Skip to main content

Guttmacher Institute

Donate Now

Highlights

  • Roe v. Wade in Peril
  • COVID-19 impact
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • U.S. policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • U.S.

Articles

  • Global research
  • U.S. research
  • Policy analysis
  • Guttmacher Policy Review
  • Op-eds & external blogs

Fact Sheets

  • Global
  • U.S.
  • U.S. State Laws and Policies

Data & Visualizations

  • Data center
  • Infographics
  • Public-use data sets

Peer-Reviewed Journals

  • International Perspectives on Sexual and Reproductive Health
  • Perspectives on Sexual and Reproductive Health

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

U.S.

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work By Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Donate stock or securites
  • Guttmacher Legacy Circle
  • Financials
  • Annual Report

Awards and Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship

Search form

Good reproductive health policy starts with credible research

 

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • Email
Guttmacher Institute

Good reproductive health policy starts with credible research

 

Donate Now

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • Email

Highlights

  • Roe v. Wade in Peril
  • COVID-19 impact
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • U.S. policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • U.S.

Articles

  • Global research
  • U.S. research
  • Policy analysis
  • Guttmacher Policy Review
  • Op-eds & external blogs

Fact Sheets

  • Global
  • U.S.
  • U.S. State Laws and Policies

Data & Visualizations

  • Data center
  • Infographics
  • Public-use data sets

Peer-Reviewed Journals

  • International Perspectives on Sexual and Reproductive Health
  • Perspectives on Sexual and Reproductive Health

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

U.S.

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work By Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Donate stock or securites
  • Guttmacher Legacy Circle
  • Financials
  • Annual Report

Awards and Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship

Search form

Contraception
July 2021

The disproportionate burdens of the mifepristone REMS

Alexandra Thompson,Center for Reproductive Rights
Dipti Singh,Lawyering Project
Adrienne R. Ghorashi,Temple University
Megan K. Donovan,Guttmacher Institute
Jenny Ma,Center for Reproductive Rights
Julie Rikelman,Center for Reproductive Rights
The time is now. Will you stand up for reproductive health and rights?
Donate Now
First published online: July 1, 2021 DOI: https://doi.org/10.1016/j.contraception.2021.05.001

Of the people who need abortion care in the United States every year, 75% are poor or living on low-incomes and approximately 60% are Black, Indigenous, and other people of color. Black, Indigenous, and other people of color face profound inequities in accessing essential health care as a result of a long history of systemic racism and discrimination. Accessing abortion is no different. Further, due to the stark racial disparities in maternal mortality and morbidity in the United States, Black and Indigenous people who cannot access the abortion care they need confront unconscionably elevated risks in carrying a pregnancy to term. Over the past year, the COVID-19 pandemic has only laid bare and deepened existing health care inequities. Unfortunately, legal barriers to abortion access at the state and federal levels exacerbate these inequities. Among these barriers are the U.S. Food and Drug Administration's (“FDA”) Risk Evaluation and Mitigation Strategy (“REMS”) restrictions for mifepristone—1 of 2 drugs used to end early pregnancy and manage a miscarriage. This Spring, the FDA announced its intention to exercise enforcement discretion for the in-person dispensing requirement of the REMS during the public health emergency. This change, although welcome, is temporary and applies only to one of the REMS restrictions. In May, the FDA stated its intention to conduct a long-awaited review of the REMS as a whole. As long as the REMS remain in place, it will unnecessarily burden access to safe medication for abortion and miscarriage care. Permanently removing the REMS in its entirety is therefore critical to reducing the disproportionate harms of abortion restrictions on communities of color and advancing equity in and access to timely and essential reproductive health care.

Full article available in Contraception
Printer-friendly version

Share

FacebookTwitterEmail

Topic

United States

  • Abortion

Geography

  • Northern America: United States
Guttmacher Institute
Reproductive rights are under attack. Will you help us fight back with facts?
Donate Now
Follow Guttmacher:

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Footer Menu

  • Privacy Policy
© 2022 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.

Get Our Updates